ESR1 and breast cancer: Enavatuzumab exhibited potent antitumor activity in multiple xenograft models, including MCF-7, an ER-positive breast cancer cell line (Fig. 3a), and HCC70, a triple-negative (ER−/PR−/HER2−) line (Fig. 3b).